Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 crossover bioavailability and food-effect study of S-606001 in healthy adults
jRCT2071240030Phase 1Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of S-606001 in Pompe disease (3 arms), sponsored by Shionogi & Co., Ltd. Primary endpoint: Pharmacokinetic parameters of S-606001. Started Jul 2024; status: active, not recruiting.
02
Drugs
S-606001
03
Conditions
Pompe disease
Beyond the preview
Go deeper on jRCT2071240030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071240030.